[1]陆 苑,潘 洁,杨淑婷,等.艾迪注射液对肝癌大鼠谷胱甘肽-S-转移酶的影响[J].中国药理学通报,2018,(08):1170-1174.[doi:10.3969/j.issn.1001-1978.2018.08.026]
 LU Yuan,PAN Jie,YANG Shu-ting,et al.Effect of Aidi injection on glutathione-S-transferase of diethylnitrosamine-induced hepatocellular carcinoma model rats[J].Chinese Pharmacological Bulletin,2018,(08):1170-1174.[doi:10.3969/j.issn.1001-1978.2018.08.026]
点击复制

艾迪注射液对肝癌大鼠谷胱甘肽-S-转移酶的影响()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2018年08期
页码:
1170-1174
栏目:
复方药物药理学
出版日期:
2018-07-26

文章信息/Info

Title:
Effect of Aidi injection on glutathione-S-transferase of diethylnitrosamine-induced hepatocellular carcinoma model rats
文章编号:
1001-1978(2018)08-1170-05
作者:
陆 苑14 潘 洁1 杨淑婷3 吴 琼3 刘春花1 李勇军2 刘 亭1
1.贵州省药物制剂重点实验室; 2.民族药与中药开发应用教育部工程研究中心; 3.贵州医科大学药学院; 4.国家苗药工程技术研究中心,贵州 贵阳 550004
Author(s):
LU Yuan14 PAN Jie1 YANG Shu-ting3 WU Qiong3 LIU Chun-hua1 LI Yong-jun2 LIU Ting1
1.Guizhou Provincial Key Lab of Pharmaceutics, Guiyang 550004,China; 2.Engineering Research Center for the Development and Application of Ethnic Medicine and TCM,Ministry of Education,Guiyang 550004,China; 3.School of Pharmacy,Guizhou Medical University, Guiyang 550004, China; 4.National Engineering Research Center of Miao's Medicines, Guiyang 550004, China
关键词:
艾迪注射液 肝细胞癌 谷胱甘肽-S-转移酶 协同作用 蛋白表达 mRNA表达
Keywords:
Aidi injection hepatocellular carcinoma glutathione-S-transferase synergistic effect protein expression mRNA expression
分类号:
R-332; R282.71; R322.47; R345.5; R735.7; R977.3; R977.6
DOI:
10.3969/j.issn.1001-1978.2018.08.026
文献标志码:
A
摘要:
目的 研究艾迪注射液(Aidi injection, ADI)对肝细胞癌(hepatocellular carcinoma, HCC)大鼠血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBil)和碱性磷酸酶(ALP)水平的影响,以及对肝组织中谷胱甘肽-S-转移酶(GSTs)活性,对GST-π mRNA和蛋白表达的影响。方法 采用95 mg·L-1二乙基亚硝胺溶液间断性给药130 d,诱导HCC大鼠模型,并通过病理切片检查来确认模型构建成功。模型成功后,实验动物分成正常组、HCC模型组和ADI组(HCC大鼠给予14 d ADI,腹腔注射,10 mL·kg-1,每日1次),正常组和模型组给予相同时间周期和相同体积的生理盐水。给药结束后16 h分离血清和肝组织,生化分析仪检测各组大鼠血清生化指标(ALT、AST、TBil、ALP); 紫外/可见分光光度计检测肝组织中还原型谷胱甘肽(GSH)与1-氯-2,4-二硝基苯(CDNB)结合后OD值,计算GSTs酶活力; qRT-PCR和Western blot法检测HCC大鼠的癌旁组织和癌灶组织,以及正常大鼠肝组织GST-π的mRNA和蛋白表达。结果 病理学检查结果显示模型构建成功。ADI可明显降低HCC大鼠血清中ALT、AST、TBil、ALP水平(P<0.01),降低肝组织中GSTs酶活性(P<0.05),降低癌灶组织中GST-π的mRNA和蛋白表达(P<0.01)。结论 ADI具有肝功能保护作用,且可通过下调GST-π的表达来降低GSTs酶活性,这可能是ADI在肝癌化疗中发挥协同作用的重要机制。
Abstract:
Aim To investigate the effects of Aidi injection(ADI)on the serum levels of ALT, AST, TBil and ALP, the activity of GSTs in liver, mRNA and the protein expression of GST-π in hepatocellular carcinoma(HCC)model rats.Methods The HCC model was induced through the oral administration of diethylnitrosamine(DEN)for 130 days in low dose, and validated by HE pathological sections.Then, the rats were divided into normal group, model group and model-ADI group.Normal saline was given to normal group and model group for 14 days, respectively.Then ADI was given to model-ADI group for 14 days.Lastly, biochemical indicators(ALT, AST, TBil, ALP)were tested in three groups.Ultraviolet visible spectrophotometry was used to determine the OD value of the bonder of reduced glutathione(GSH)and 1-chloro-2,4-two nitrobenzene(CDNB)for the evaluation of GSTs enzyme activity in liver tissues.qRT-PCR and Western blot was used to determine the expression of GST-π in normal liver tissues, para-cancerous tissues and cancerous tissues of rats.Results The HCC model was established successfully.The levels of ALT, AST, TBil and ALP were down-regulated markedly in the serum of HCC rats by ADI.In addition, the enzyme activity of GSTs, and the mRNA/protein expression of GST-π were reduced significantly by ADI.Conclusion ADI could reduce the activity of GSTs through down-regulating the expression of GST-π in HCC rats, which may be the underlying mechanism for the synergistic effect of ADI.

参考文献/References:

[1] Zhang H, Zhou Q, Lu Y Y, et al.Aidi injection alters the expression profiles of microRNAs in human breast cancer cells[J].J Tradit Chin Med, 2011, 31(1):10-6.
[2] Xu H X, Huang X E, Li Y, et al.A clinical study on safety and efficacy of Aidi injection combined with chemotherapy [J].Asian Pac J Cancer Prev, 2011, 12(9):2233-6.
[3] 程宏文, 骆明莲, 江 涛, 等.艾迪注射液联合FOLFOX4化疗治疗原发性肝癌疗效观察 [J].现代肿瘤医药, 2012, 20(4):777-9.
[3] Cheng H W, Luo M L, Jiang T, et al.Effect of Aidi injection combined with FOLFOX4 chemotherapy in the treatment of primary liver cancer [J].J Mod Oncol, 2012,20(4):777-9.
[4] 冯献明, 付方现, 刘俊叶, 等.艾迪注射液联合5-氟尿嘧啶加顺铂化疗方案治疗中晚期肝癌 [J].新乡医学院学报, 2010, 27(3):273-5.
[4] Feng X M, Fu F X, Liu J Y, et al.Aidi injection combined with 5-fluorouracil and cisplatinum for advanced liver cancer [J].J Xinxiang Med Coll, 2010, 27(3):273-5.
[5] 吴 霞, 李 慧.不同剂量艾迪注射液治疗原发性肝癌晚期的疗效观察[J].现代中西医结合杂志, 2011, 20(36): 4665-6.
[5] Wu X, Li H.Efficacy of different doses of Aidi injection in the treatment of advanced primary liver cancer [J].Mod J Integr Tradit Chin West Med, 2011, 20(36):4665-6.
[6] 王 沛, 李晓天, 张莉蓉.miRNAs对药物代谢酶的转录后调控[J].中国药理学通报, 2015, 31(8):1037- 40.
[6] Wang P, Li X T, Zhang L R.The post-transcriptional regulation of microRNAs on drug metabolic enzyme[J].Chin Pharmacol Bull, 2015,31(8):1037-40.
[7] Filomeni G, Turella P, Dupuis M L, et al.6-(7-Nitro- 2,1,3-benzoxadiazol- 4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance(MDR)-associated protein 1-mediated MDR in small cell lung cancer [J].Mol Cancer Ther, 2008,7(2):371-9.
[8] Ricci G, De Maria F, Antonini G, et al.7-Nitro- 2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione-S-transferase.Mechanism of action of potential anticancer drugs [J].J Biol Chem, 2005,280(28):26397-405.
[9] Gyamfi M A, Ohtani I I, Shinno E, et al.Inhibition of glutathione-S-transferases by thonningianin A, isolat from the African medicinal herb, Thonningia sanguinea, in vitro[J].Food Chem Toxicol, 2004, 42(9):1401-8.
[10] Salinas-Souza C, Petrilli A S, de Toledo S R.Glutathione S-transferase polymorphisms in osteosarcoma patients [J].Pharmacogenet Genomics, 2010, 20(8):507-15.
[11] Seitz G, Bonin M, Fuchs J, et al.Inhibition of glutathione S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma [J].Int J Oncol, 2010, 36(2):491-500.
[12] 杨富春, 郑树森, 蒋天安.改良法大鼠原发性肝癌模型的建立[J].中华医学杂志, 2004, 84(23):2018-9.
[12] Yang F C, Zheng S S, Jiang T A.The establishment of primary liver cancer model in rats improved method[J].Natl Med J China, 2004, 84(23):2018-9.
[13] 罗 明, 贺 平, 吴孟超, 等.苦参碱和氧化苦参碱对二乙基亚硝胺诱发大鼠肝癌作用的影响[J].中国药理学通报, 2000, 16(4):416-7.
[13] Luo M, He P, Wu M C, et al.Effects of matrine and oxymatrine on DEN induced liver cancer in rats[J].Chin Pharmacol Bull, 2000, 16(4):416-7.
[14] 朱艳志, 孔宪炳, 颜 朗.间断给药DEN诱导大鼠肝癌模型建立及病理研究[J].重庆医科大学学报, 2010, 35(12):1843-6.
[14] Zhu Y Z, Kong X B, Yan L.Establishment of hepatocarcinoma rat model induced by diethylmitrosamine discontinuously and pathological study [J].J Chongqing Med Univ, 2010,35(12):1843-6.
[15] Nakatani T, Roy G, Fujimoto N, et al.Sex hormone dependency of diethylnitrosamine induced liver tumors in mice and chemoprevention by leuprorelin [J].Jpn J Cancer Res, 2001, 92(3):249-56.

相似文献/References:

[1]夏丽洁,张富春.肝癌治疗新靶点GPC3研究进展[J].中国药理学通报,2016,(11):1486.[doi:10.3969/j.issn.1001-1978.2016.11.002]
 XIA Li-jie,ZHANG Fu-chun.Research progress of a new therapeutic target in hepatocellular carcinoma glypican-3[J].Chinese Pharmacological Bulletin,2016,(08):1486.[doi:10.3969/j.issn.1001-1978.2016.11.002]
[2]孙嘉玲,文 彬,孙海涛,等.miRNAs与肝细胞癌的相关性研究进展[J].中国药理学通报,2017,(04):445.[doi:10.3969/j.issn.1001-1978.2017.04.001]
 SUN Jia-ling,WEN Bin,SUN Hai-tao,et al.Research progress of relevance between miRNAs and hepatocellular carcinoma[J].Chinese Pharmacological Bulletin,2017,(08):445.[doi:10.3969/j.issn.1001-1978.2017.04.001]
[3]吕 峰,王 伟,艾麦提.牙森,等.MicroRNA-155 在肝细胞癌对索拉非尼抗药中的作用研究[J].中国药理学通报,2017,(05):657.[doi:10.3969/j.issn.1001-1978.2017.05.014]
 LYU Feng,WANG Wei,AI Mai Ti·Ya Sen,et al.Effect of microRNA-155 on sorafenib resistance in hepatocellular carcinoma[J].Chinese Pharmacological Bulletin,2017,(08):657.[doi:10.3969/j.issn.1001-1978.2017.05.014]
[4]马 滢,方 萌,伍 超,等.丹酚酸B调控pSmad3C/pSmad3L发挥抗肝纤维化-肝细胞癌作用[J].中国药理学通报,2018,(01):44.[doi:10.3969/j.issn.1001-1978.2018.01.011]
 MA Ying,FANG Meng,WU Chao,et al.Salvianolic acid B exerts anti-hepatic fibrosis-carcinoma effect via mediation of pSmad3C/pSmad3L[J].Chinese Pharmacological Bulletin,2018,(08):44.[doi:10.3969/j.issn.1001-1978.2018.01.011]
[5]陆 苑,潘 洁,杨淑婷,等.UPLC-MS法研究艾迪注射液对大鼠体内阿霉素药代动力学的影响[J].中国药理学通报,2018,(03):423.[doi:10.3969/j.issn.1001-1978.2018.03.024]
 LU Yuan,PAN Jie,YANG Shu-ting,et al.Effect of Aidi injection on in vivo pharmacokinetics of doxorubicin in Sprague-Dawley rats by UPLC-MS method[J].Chinese Pharmacological Bulletin,2018,(08):423.[doi:10.3969/j.issn.1001-1978.2018.03.024]
[6]王 玲,贾 岩,李蒙蒙,等.铁死亡在肝细胞癌中的作用以及研究进展[J].中国药理学通报,2018,(06):745.[doi:10.3969/j.issn.1001-1978.2018.06.002]
 WANG Ling,JIA Yan,LI Meng-meng,et al.Research progress in role and mechanism of ferroptosis in hepatocellular carcinoma[J].Chinese Pharmacological Bulletin,2018,(08):745.[doi:10.3969/j.issn.1001-1978.2018.06.002]
[7]李未祥,周大臣,王 石,等.七叶皂苷钠通过CARMA3/NF-κB信号通路抑制肝癌细胞的增殖[J].中国药理学通报,2018,(09):1243.[doi:10.3969/j.issn.1001-1978.2018.09.012]
 LI Wei-xiang,ZHOU Da-chen,WANG Shi,et al.Sodium aescinate inhibits proliferation of hepatocellular carcinoma through CARMA3/NF-κB signaling pathway[J].Chinese Pharmacological Bulletin,2018,(08):1243.[doi:10.3969/j.issn.1001-1978.2018.09.012]

备注/Memo

备注/Memo:
收稿日期:2018-03-22,修回日期:2018-04-25
基金项目:大学生创新创业训练计划项目(No 201510660006); 贵州省科技合作计划项目(黔科合LH字[2015]7361); 贵阳市科技计划项目(筑科合同[20141001]09号); 贵州省科学技术厅人才团队项目(黔科合平台人才[2016]5613\5677)
作者简介:陆 苑(1988-),女,博士,讲师,研究方向:中药药效物质基础与药代动力学,E-mail: 314521537@qq.com;
刘 亭(1981-),男,博士,副教授,硕士生导师,研究方向:中药药理学,通讯作者,E-mail: t-liu@163.com
更新日期/Last Update: 2018-07-26